After the books closed: the quarter's biggest news happened too late to be in the numbers
The model's full reasoning — Q3 2016 call → NOWe need to determine if management reports that the most important positive developments of the period happened so late in the reported period or shortly after it ended that the results being presented contain little or none of their effect, with management itself marking the timing. We need to look for management's own words indicating late-breaking positive events that are concrete and that management treats as the real story the numbers missed. In the transcript, Scott Koenig mentions several updates. He says: "I am pleased to announce the on time filing and FDA clearance of an investigation of new drug application for MGA012 and we’ve remained on track to submit two additional INDs in 2107." That's a positive development, but is it late in the period? He says "on time filing and FDA clearance" - but does he specify timing? He says "we ended the quarter with nine programs in clinical development" and "we are pleased to be meeting our goal of submitting at least one IND per year in 2016 with the expectation that we’ll submit two more in 2017." That seems like a routine update. He also mentions: "we announced in our earnings release today that we plan to host an R&D Day in New York on Tuesday, December 13" - that's future. He mentions: "we are pleased to announce that this program was recently approved to expand into the first of three Asian countries. We’re specific in opening trial sites in Korea soon and believe approvals for Taiwan and Singapore will follow." That's about margetuximab combination trial. "recently approved" - but is that late in the period? He doesn't specify exact timing. He mentions: "we are pleased to announce that the combination study with pembrolizumab has advanced into dose expansion cohorts, while the enoblituzumab study is completing the last dose-escalation cohort." That's a positive development, but again no specific timing. He mentions: "MacroGenics recently dealt the last subject in the final cohort of our Phase 1 study of MGD010." That's "recently" - but again no specific timing. He mentions: "we expect to bid an IND for MGD014 in the first half of 2017" - that's future. He mentions: "The other 2017 IND submission will be for MGD013" - future. He mentions: "we ended the quarter with a strong balance sheet" - not a late event.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASM | Avino Silver & Gold Mines Ltd. | Q4 2023 | 2024-03-21 | C+ |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| NBTX | Nanobiotix S.A. | Q2 2023 | 2023-09-27 | D |
| SWBI | Smith & Wesson Brands, Inc. | Q1 2023 | 2022-09-08 | C+ |
| YMM | Full Truck Alliance Co. Ltd. | Q2 2022 | 2022-08-25 | C+ |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| BFIN | BankFinancial Corporation | Q1 2022 | 2022-05-06 | A |
| RNW | ReNew Energy Global Plc | Q2 2022 | 2021-11-18 | C |
| BFI | BurgerFi International, Inc. | Q3 2021 | 2021-11-12 | C |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
OPK · Q1 2022 → YESThe question is: Does management report that the MOST IMPORTANT POSITIVE DEVELOPMENTS of the period happened SO LATE IN THE REPORTED PERIOD, OR SHORTLY AFTER IT ENDED, that the results being presented...YES The transcript shows management treating the ModeX acquisition (announced and closed on the call date, May 9) and the Sema4/GeneDx deal (closed April 29) as major positive developments that occurred after the Q1 period ended. These are framed as key steps toward unlocking value and are highlighted as the "exciting announcement" that changed the call format.
RNW · Q2 2022 → YESThe question is: Does management report that the MOST IMPORTANT POSITIVE DEVELOPMENTS of the period happened SO LATE IN THE REPORTED PERIOD, OR SHORTLY AFTER IT ENDED, that the results being presented...YES The transcript shows management explicitly marking the timing of key positive developments: 400 MW commissioned "since the end of the quarter" (bringing operating capacity to 7 GW today, with another 400 MW scheduled "over the next couple of weeks"), plus the completed Telangana acquisition adding 260 MW.
ASM · Q4 2023 → YESThe question is: Does management report that the MOST IMPORTANT POSITIVE DEVELOPMENTS of the period happened SO LATE IN THE REPORTED PERIOD, OR SHORTLY AFTER IT ENDED, that the results being presented...